Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)

Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02448758

Acronym

CB(NPC)²

Enrollment

518

Registered

2015-05-19

Start date

2013-11-01

Completion date

2017-09-01

Last updated

2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Keywords

mutation

Brief summary

The investigators propose to create a database at the regional level, the principle is to include all patients in whom a mutation was detected from a single platform (Lille). The creation of this regional cohort, smaller than the national cohort of Biomarkers France, will perform a more comprehensive collection of clinical data, and molecular monitoring data of patients included. To increase the completeness of the collection of information, it will not be based on voluntary prescribing clinician but will be largely carried out by CRA dedicated to this activity.

Detailed description

This is a prospective and retrospective study of a population of patients with mutated non-small cell lung cancer in the Nord Pas de Calais. Retrospective cohort will involve patients with main molecular abnormalities, identifiable from molecular biology platform CRRC, except EGFR and KRAS treated from September 2011 to February 2013.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Aged ≥ 18 years old * Patient with non-small cell lung cancer * Detected in the Nord Pas de Calais * Monitored in the Nord Pas de Calais * Patient must have signed a non-opposition form to the use of medical data

Exclusion criteria

\- No identified mutation

Design outcomes

Primary

Measure	Time frame	Description
Correlation between clinical factors and mutation status	at baseline	The clinical factors are age, smoking status, occupational and environmental exposure, personal and family background, TNM stage, performance status

Secondary

Measure	Time frame
Progression-free survival	3 years
Overall survival	3 years
Number of patients included in a clinical trial dedicated to a certain type of non-small cell lung cancer with mutation	3 years
Number of cases per mutation type	3 years

Countries

France

Contacts

STUDY_DIRECTORAlexis CORTOT, MD, PhD

CHRU of Lille

STUDY_DIRECTOREric Dansin, MD

Centre Oscar Lambret

Outcome results